Search Results 311-320 of 12296 for Multiple myeloma red flag

  1. Health Topics - Mayo Clinic News Network

    Multiple myeloma is the second-most common blood cancer, and the risk is ... Expert alert: 5 reasons more diverse organ donors are needed featured image. Featured ...

  2. A Study Of Oral LGH447 In Patients With Relapsed And/or Refractory Multiple Myeloma - Mayo Clinic

    ... Multiple Myeloma (MM). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

  3. What is monoclonal gammopathy of renal significance (MGRS)?

    Learn what monoclonal gammopathy of renal significance (MGRS) means, how it affects the kidneys, and how it differs from MGUS and multiple myeloma.

  4. Florida - 2017 Archives - Mayo Clinic News Network

    Study identifies barriers to transplant therapy to treat multiple myeloma among racial minority groups. Joe Dangor. December 11, 2017. ATLANTA – A study by ...

  5. Study To Evaluate The Safety And Efficacy Of KITE-585 In Participants With Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    Study To Evaluate The Safety And Efficacy Of KITE-585 In Participants With Relapsed/Refractory Multiple Myeloma · Overview · Participation eligibility.

  6. BT062 In Combination With Lenalidomide Or Pomalidomide And Dexamethasone In Patients With Multiple Myeloma - Mayo Clinic

    Clinical Trials · BT062 In Combination With Lenalidomide Or Pomalidomide And Dexamethasone In Patients With Multiple Myeloma · More about research at Mayo Clinic.

  7. A Study To Evaluate The Safety And Effectiveness Of Anti-CD38 CAR-T In Relapsed Or Refractory Multiple Myeloma Patients - Mayo Clinic

    A Study To Evaluate The Safety And Effectiveness Of Anti-CD38 CAR-T In Relapsed Or Refractory Multiple Myeloma Patients ... Multiple Myeloma. Participation ...

  8. Ide-cel, a BCMA-directed CAR-T cell therapy, shows favorable risk-benefit profile and response - Mayo Clinic

    This study was the first multicenter study of CAR -T cell therapy in multiple myeloma in the U.S., with Mayo Clinic as one of the initial and leading enrollment ...

  9. A Study Of Daratumumab, Bortezomib, Lenalidomide And Dexamethasone (DVRd) Followed By Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide And Dexamethasone (DVRd) Followed By Autologous Stem Cell Transplant (ASCT) In Participants With Newly Diagnosed Multiple Myeloma - Mayo Clinic

    ... Multiple Myeloma. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview. Tab ...

  10. Novel Support Options In Autologous Stem Cell Transplant For Multiple Myeloma - Mayo Clinic

    ... multiple myeloma undergoing autologous stem cell transplantation? Participation eligibility. Participant eligibility includes age, gender, type and stage of ...